New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
12:10 EDTSNYSanofi announces Nasacort now available in U.S. without prescription
Sanofi and its U.S. consumer healthcare division Chattem announced earlier that Nasacort Allergy 24HR Nasal Spray is now available over-the-counter in the U.S. to relieve the full range of seasonal and year-round nasal allergy symptoms, including nasal congestion, in adults and children 2 years of age and older. Nasacort Allergy 24HR is the first and only medicine in its class to be available at full prescription strength without the need for a prescription, the company stated.
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
10:38 EDTSNYSanofi announces agreement with NHS England on cabazitaxel
Sanofi announced that it has reached agreement with NHS England that cabazitaxel will once more be available on the NHS to clinically eligible men with advanced prostate cancer. Cabazitaxel was de-listed from the Cancer Drugs Fund by NHS England on March 12, however in order to support access to cabazitaxel during the transition period to a formal NICE appraisal outcome, Sanofi and NHS England have come to an agreement that will enable provision of cabazitaxel to patients in England. NICE has agreed to review the Technology Appraisal for cabazitaxel and we expect a result in 2016. Sanofi has submitted a Patient Access Scheme as part of the re-appraisal of cabazitaxel by NICE. Sanofi also plans to re-submit cabazitaxel to the Scottish Medicines Consortium in 2015 to allow patients in Scotland access to this important medicine.
May 27, 2015
12:36 EDTSNYOn The Fly: Top stock stories at midday
Subscribe for More Information
08:01 EDTSNYRetrophin agrees to sell Pediatric PRV to Sanofi
Retrophin (RTRX) announced an agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sanofi (SNY). Retrophin received the Pediatric PRV when Cholbam was approved by the U.S. FDA for the treatment of pediatric and adult patients suffering from bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disorders. Upon closing of the transaction, Retrophin will receive a payment of $150M, followed by two equal installments of $47.5M in 2016 and 2017. The company will receive a total consideration of $245M in cash from Sanofi in exchange for the Pediatric PRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases. The transaction is subject to customary closing conditions and clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
May 26, 2015
08:14 EDTSNYBoston Biotech Conferences to hold a conference
Subscribe for More Information
08:01 EDTSNYSanofi's Genzyme to present Aubagio, Lemtrada data at CMSC
Subscribe for More Information
May 22, 2015
10:52 EDTSNYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
May 21, 2015
14:48 EDTSNYRegeneron primary driver remains Praluent, says Piper Jaffray
Piper Jaffray noted that Regeneron (REGN) shares are at all-time highs after the company and partner Sanofi reported Phase IIb data on Dupilumab and Phase III data on Sarilumab. However, the firm believes the primary driver for Regeneron remains Praluent and firm expects launch costs to outstrip sales growth. Piper acknowledges Regeneron has "one of the richest pipelines in all of biotech," but it sees risk around Amgen's (AMGN) patent suit and keeps its Neutral rating and $484 price target on the stock.
05:15 EDTSNYRegeneron, Sanofi announce positive topline results from sarilumab Phase 3 study
Subscribe for More Information
May 19, 2015
06:55 EDTSNYGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
12:34 EDTSNYRegeneron, Sanofi announce positive pivotal Phase 2b dupilumab data in asthma
Subscribe for More Information
May 17, 2015
14:59 EDTSNYL'Oreal CEO 'ready' to sell Sanofi stake if needed, Barron's says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use